Altimmune, Inc. reported $41K of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $41K (to Q4 2025). Net income: −$92M, trailing twelve months to Q2 2026. Free cash flow: −$77M, trailing twelve months to Q2 2026. Operating margin: −355762%, trailing twelve months to Q4 2025.

ALTAltimmune, Inc.

Healthcare

$2.60-34% 1Y

$2.60

$2.5952 weeks$6.18

ALT as reported

Altimmune, Inc. reported $41K of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$41K

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$92M
Net income · +4.6% year on year · trailing twelve months to Q2 2026
Free cash flow: −$77M
Free cash flow · trailing twelve months to Q2 2026
Operating margin: −355762%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for ALT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$41K	n/a	Q4 2025
Net income	−$92M	+4.6%	Q2 2026
EPS	−$0.77	−35%	Q2 2026
Operating margin	−355762%	n/a	Q4 2025
Net margin	−329981%	n/a	Q4 2025
ROE	−34%	n/a	Q2 2026
ROA	−29%	n/a	Q2 2026
ROIC	433%	n/a	Q2 2026
Free cash flow	−$77M	n/a	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.